Drug intelligence / Profile preview

pioglitazone + glimepiride

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

Pioglitazone + glimepiride is a fixed-dose oral combination medication used to treat type 2 diabetes mellitus as an adjunct to diet and exercise. It contains two active ingredients: - Pioglitazone, a thiazolidinedione that increases insulin sensitivity in fat, muscle, and liver cells. - Glimepiride, a sulfonylurea that stimulates the pancreas to release more insulin. This combination is indicated for adults with type 2 diabetes who are already treated with both drug classes or have inadequate glycemic control on either agent alone. It is not effective for type 1 diabetes or diabetic ketoacidosis. The most common side effects include upper respiratory tract infections, hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas), and edema (swelling)[1][4][5][8].

Brand names
DuetactTandemact
Other names
pioglitazone/glimepirideglimepiride and pioglitazone
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)KATP channel (ATP-sensitive potassium channel)

Beyond the preview

Go deeper on pioglitazone + glimepiride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pioglitazone + glimepiride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call